Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02632864
Other study ID # 2015-08-004
Secondary ID
Status Recruiting
Phase Phase 2
First received December 7, 2015
Last updated April 11, 2018
Start date December 2015
Est. completion date November 2022

Study information

Verified date April 2018
Source Samsung Medical Center
Contact Joon Hyeok Lee, MD, PhD
Phone 82-2-3410-3409
Email gijhlee.lee@samsung.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The standard treatment of unresectable hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE) or sorafenib. Though the TACE and the agent showed survival benefit in several randomized phase III trials, the benefit was modest.

Recently, radiotherapy (RT), especially conformal and higher dose with the advancement of RT techniques, showed favorable response rate with acceptable local control rate. Based on those promising results, RT was actively applied in HCC who are not indicated with surgery and/or radiofrequency ablation.

Many researchers reported that there is a relationship between RT dose and tumor response rate. RT dose, however, is frequently limited because the complications (like radiation induced liver disease (RILD), radiation induced gastro-duodenal toxicity, etc.) are also closely related with higher exposed RT dose.

Proton beam has characteristic depth-dose distribution contrast to photon, the "Bragg peak". The advantage of this dose distribution could be more highlighted in HCC management, because of the weakness and maintenance importance of liver function itself in HCC patients. In fact, the superior results of proton beam therapy in HCC were constantly reported in several groups as prospectively as well as retrospectively.

In this background, the investigators planned the present study to evaluate the efficacy and safety of proton beam therapy in HCC patients who are not indicated with surgery and/or radiofrequency ablation (RFA).


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date November 2022
Est. primary completion date October 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Hepatocellular carcinoma (HCC) patients (Pathologically proven or HCC diagnosed based on American Association for the Study of Liver Diseases (AASLD) guideline)

- Not indicated with surgical resection and/or RFA

- Discussion in tumor board including gastroenterologist, radiologist, radiation oncologist

- Eastern Cooperative Oncology Group performance status 0 to 2 within 1 week before participate

- Adequate bone marrow function (absolute neutrophil count = 1.0 x 109/l, platelet = 30 x 109/l, hemoglobin = 8 g/dl)

- Adequate liver/renal function within 1 week before participate

- Total bilirubin <3.0 mg/dL, Prothrombin time/International normalized ratio <1.7, Albumin=2.8g/dL, Aspartate aminotransferase/alanine aminotransferase<6 times of upper normal limit Serum creatinine < 1.5 x upper normal limit, glomerular filtration rate > 50 ml/min

- Informed consent

- If viable tumor is single, 1 cm to 10 cm

- Less than 3 nodules

- Child-Pugh class A, B, or early C (score = 10)

- Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of RT

Exclusion Criteria:

- Uncontrolled hepatic encephalopathy

- Previous history of upper abdominal radiotherapy

- Status of pregnancy or breast feeding

- Less than 12 weeks of expected survival

- Uncontrolled ascites

- Combined with disease known as radiosensitive disorder (connective tissue disorder, Ataxia-telangiectasia)

- Hard to maintain stable respiration less than 5 minutes related with respiratory disease

- Combined with uncontrolled severe acute disease other than liver

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Proton arm
Proton beam therapy

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary two-year overall survival two-year after proton beam therapy
Secondary 1 month objective response rate Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. 1 month after proton beam therapy
Secondary 3 month objective response rate Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. 3 months after proton beam therapy
Secondary 6 month objective response rate Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. 6 months after proton beam therapy
Secondary 1 year progression free survival Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. one-year after proton beam therapy
Secondary 1 year local progression free survival Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. one-year after proton beam therapy
Secondary 6 months adverse event Common Terminology Criteria for Adverse Event v4.0 (CTCAE v4.0) will be used. 6 months after proton beam therapy
Secondary 1 year adverse event Common Terminology Criteria for Adverse Event v4.0 (CTCAE v4.0) will be used. 1 year after proton beam therapy
Secondary Baseline Quality of life assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ C-30) Within 2 week before proton beam therapy started
Secondary 1 month Quality of life assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ C-30) compared with baseline 1 month after proton beam therapy
Secondary 3 month Quality of life assessment by EORTC QLQ C-30 compared with baseline 3 month after proton beam therapy
Secondary 6 month Quality of life assessment by EORTC QLQ C-30 compared with baseline 6 month after proton beam therapy
Secondary Baseline Indocyanine green (ICG) ICG Retention rate at 15 minute will be used. Within 2 week before proton beam therapy started
Secondary Indocyanine green (ICG) test change compared with baseline ICG Retention rate at 15 minute will be used. 3 month after proton beam therapy
Secondary Baseline hepatobiliary phase signal Hepatobiliary phase (20 minute after gadoxetate disodium injection) will be used to evaluate functioning liver volume. Within 2 week before proton beam therapy started
Secondary Hepatobiliary phase signal change after proton beam therapy Hepatobiliary phase (20 minute after gadoxetate disodium injection) will be used to evaluate functioning liver volume. 3 month after proton beam therapy
See also
  Status Clinical Trial Phase
Completed NCT02557724 - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Terminated NCT04702230 - Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
Active, not recruiting NCT01217034 - Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib Phase 2
Recruiting NCT05169177 - Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
Withdrawn NCT02599909 - Gut Microbiota in People With Hepatocellular Carcinoma (HCC)
Terminated NCT03998033 - Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma Phase 1
Recruiting NCT04010071 - Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors Phase 2
Recruiting NCT04864054 - T-Cell Therapy (ECT204) in Adults With Advanced HCC Phase 2
Terminated NCT04187937 - Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections N/A
Completed NCT02471313 - Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization Phase 2
Completed NCT00001576 - A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver Phase 1
Recruiting NCT01542281 - Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer N/A
Recruiting NCT03803436 - Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation Phase 2
Completed NCT05495529 - Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
Completed NCT02571946 - Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis N/A
Not yet recruiting NCT01180088 - Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy N/A
Withdrawn NCT00510627 - Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases Phase 4
Completed NCT05848947 - SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA Phase 4
Not yet recruiting NCT05723705 - Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
Terminated NCT04502082 - Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) Phase 1/Phase 2